Acid dissociation constant

KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat

Retrieved on: 
Wednesday, October 19, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, U.S. Securities and Exchange Commission, DME, Acid dissociation constant, American Chemical Society, Tmax, Protease, NASDAQ, HAE, Security (finance), Annual report, Plasma kallikrein, Private Securities Litigation Reform Act, Form 10-K, Diabetic retinopathy, Hereditary angioedema, Absorption, Journal of Medicinal Chemistry, Safety, American, Journal, Plasma, Medicinal chemistry, Forward-looking statement, Metabolism, FDA, COVID-19, Risk, Xenobiotic, Toxicology, KALV, Pharmaceutical industry

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the publication of new sebetralstat data in both the Journal of Medicinal Chemistry and Xenobiotica.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the publication of new sebetralstat data in both the Journal of Medicinal Chemistry and Xenobiotica.
  • The Journal of Medicinal Chemistry article focuses on the medicinal chemistry KalVista conducted that led to the discovery of sebetralstat, with properties optimized for the on-demand treatment of hereditary angioedema (HAE).
  • These foundational papers further demonstrate the promise of sebetralstat for the on-demand treatment of HAE attacks, said Andrew Crockett, Chief Executive Officer of KalVista.
  • Additional details can be found in the manuscripts, which are available at:
    The Journal of Medicinal Chemistry is a biweekly peer-reviewed medical journal published by the American Chemical Society covering research in medicinal chemistry.

KalVista Pharmaceuticals Presents New Data for Sebetralstat and its Oral Factor XIIa Inhibitor Program

Retrieved on: 
Tuesday, July 5, 2022
Research, Diabetes, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Department, Plasma kallikrein, Mouse, FDA, HAE, HK, University of Leeds, Physiology, Adult, DME, Hereditary angioedema, Edema, COVID-19, Population, Internal medicine, U.S. Securities and Exchange Commission, Annual report, Forward-looking statement, PK, KKS, Teaching hospital, Acid dissociation constant, KALV, Volunteering, Factor XII, University, Rheumatology, Fasting, Doctor of Philosophy, Attack, Safety, Risk, Private Securities Litigation Reform Act, NASDAQ, Form 10-K, Diabetic retinopathy, Angioedema, MD, Program, Security (finance), Time-invariant system, Pharmaceutical industry, Information technology, Patient, Adolescence

Animal model data with oral FXIIa inhibitor KV998086 showed the compound protected mice from kallikrein-kinin system (KKS) mediated edema.

Key Points: 
  • Animal model data with oral FXIIa inhibitor KV998086 showed the compound protected mice from kallikrein-kinin system (KKS) mediated edema.
  • The population PK study is important for our sebetralstat program, said Andrew Crockett, Chief Executive Officer of KalVista.
  • KalVista is developing sebetralstat as an oral on-demand therapy for acute HAE attacks and is enrolling the Phase 3 KONFIDENT clinical trial.
  • In addition, KalVistas oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients.

KalVista Pharmaceuticals Presents Promising Preclinical Data for Oral Factor XIIa Inhibitor Program

Retrieved on: 
Wednesday, June 8, 2022
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Angioedema, Form 10-K, Time-invariant system, Annual report, KKS, Forward-looking statement, Oral, Security (finance), Plasma kallikrein, Disease, Treatment, U.S. Securities and Exchange Commission, HAE, Hereditary angioedema, Diabetic retinopathy, KALV, FDA, Patient, Private Securities Litigation Reform Act, COVID-19, Risk, Research, NASDAQ, Acid dissociation constant, DME, Safety, Pharmaceutical industry, Information technology

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented data for its oral Factor XIIa (FXIIa) and plasma kallikrein (PKa) inhibitor programs at the KININ2022 conference in Annecy, France.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented data for its oral Factor XIIa (FXIIa) and plasma kallikrein (PKa) inhibitor programs at the KININ2022 conference in Annecy, France.
  • Presentations for oral FXIIa inhibitors showed that the compounds block the initiation and amplification of the kallikrein kinin system (KKS) in preclinical models.
  • The following posters were presented at KININ2022:
    Oral factor XIIa inhibition blocks angiotensin converting enzyme inhibitor induced angioedema in mouse.
  • In addition, KalVistas oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients.